ENANTA PHARMACEUTICALS INC cotiza a 11.52 USD y tiene una capitalización bursátil de $335M. En los últimos 12 meses ha facturado $65M con un margen de flujo de caja libre del -49.2%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and ED…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.67 | $-0.45 | $-0.42 |
| Estimado | $-0.77 | $-0.53 | $-0.57 | $-0.80 |
| Sorpresa | — | -26.4% | +21.1% | +47.5% |
| Métrica | ENTA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -130.7% | -38.6% | -92.0% |
| Net Margin | -125.4% | -33.6% | -91.8% |
| FCF Margin | -49.2% | -13.9% | -35.4% |
| ROE | -126.5% | -40.4% | -86.1% |
| ROA | -29.2% | -32.0% | +2.8% |
| Current Ratio | 4.21 | 2.84 | +1.37 |
| Debt / Equity | — | 0.28 | — |